Financial Ratios Bloomage BioTechnology Corporation Limited
Stocks
688363
CNE100003NL9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.70 CNY | +2.81% |
|
-1.89% | -20.56% |
| May. 19 | Eternity Investment says executive directors to retire at AGM | RE |
| Apr. 29 | Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.09 | 7.43 | 4.16 | 1.7 | 1.69 | |||||
Return on Total Capital | 8.48 | 9.19 | 5 | 2.02 | 2.01 | |||||
Return On Equity % | 14.47 | 15.52 | 8.53 | 2.44 | 4.17 | |||||
Return on Common Equity | 14.6 | 15.75 | 8.73 | 2.53 | 4.2 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 77.4 | 76.69 | 72.69 | 72.4 | 67.8 | |||||
SG&A Margin | 55.3 | 54.07 | 54.82 | 58.05 | 48.94 | |||||
EBITDA Margin % | 17.56 | 17.66 | 12.7 | 8.67 | 12.8 | |||||
EBITA Margin % | 15.51 | 15.37 | 9.67 | 4.67 | 6.07 | |||||
EBIT Margin % | 15.15 | 15.12 | 9.38 | 4.33 | 5.6 | |||||
Income From Continuing Operations Margin % | 15.67 | 15.12 | 9.59 | 3.14 | 6.93 | |||||
Net Income Margin % | 15.81 | 15.27 | 9.75 | 3.24 | 6.96 | |||||
Net Avail. For Common Margin % | 15.81 | 15.27 | 9.75 | 3.24 | 6.96 | |||||
Normalized Net Income Margin | 9.85 | 10.16 | 6.38 | 2.85 | 3.66 | |||||
Levered Free Cash Flow Margin | 19.37 | -3.58 | -10.21 | -5.32 | 5.27 | |||||
Unlevered Free Cash Flow Margin | 19.51 | -3.43 | -10.1 | -5.21 | 5.36 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.75 | 0.79 | 0.71 | 0.63 | 0.48 | |||||
Fixed Assets Turnover | 2.78 | 2.44 | 1.85 | 1.37 | 1.01 | |||||
Receivables Turnover (Average Receivables) | 12.51 | 14.79 | 13.38 | 10.75 | 7.53 | |||||
Inventory Turnover (Average Inventory) | 1.89 | 1.58 | 1.45 | 1.24 | 1.21 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.84 | 2.45 | 2.56 | 2.04 | 2.34 | |||||
Quick Ratio | 2.2 | 1.61 | 1.47 | 1 | 1.38 | |||||
Operating Cash Flow to Current Liabilities | 0.91 | 0.39 | 0.57 | 0.42 | 0.53 | |||||
Days Sales Outstanding (Average Receivables) | 29.19 | 24.68 | 27.28 | 34.05 | 48.47 | |||||
Days Outstanding Inventory (Average Inventory) | 193.53 | 230.33 | 252.56 | 294.15 | 300.74 | |||||
Average Days Payable Outstanding | 49 | 46.35 | 48.59 | 43.84 | 56.43 | |||||
Cash Conversion Cycle (Average Days) | 173.72 | 208.67 | 231.25 | 284.36 | 292.77 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 5.26 | 5.83 | 2.98 | 5.26 | 4.8 | |||||
Total Debt / Total Capital | 5 | 5.51 | 2.89 | 5 | 4.58 | |||||
LT Debt/Equity | 3.75 | 2.4 | 0.79 | 3.19 | 1.89 | |||||
Long-Term Debt / Total Capital | 3.56 | 2.27 | 0.76 | 3.03 | 1.8 | |||||
Total Liabilities / Total Assets | 24 | 23.02 | 17.55 | 20.99 | 18.15 | |||||
EBIT / Interest Expense | 67.62 | 66.2 | 53.11 | 25.33 | 36.66 | |||||
EBITDA / Interest Expense | 81.45 | 80.82 | 77.4 | 57.37 | 91.21 | |||||
(EBITDA - Capex) / Interest Expense | 10.7 | 32.87 | -18.57 | -21.27 | 40.46 | |||||
Total Debt / EBITDA | 0.33 | 0.33 | 0.25 | 0.68 | 0.58 | |||||
Net Debt / EBITDA | -2.61 | -1.49 | -1.32 | -0.74 | -1.17 | |||||
Total Debt / (EBITDA - Capex) | 2.53 | 0.82 | -1.04 | -1.84 | 1.31 | |||||
Net Debt / (EBITDA - Capex) | -19.84 | -3.66 | 5.52 | 2 | -2.65 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 87.93 | 28.53 | -4.45 | -11.61 | -21.82 | |||||
Gross Profit, 1 Yr. Growth % | 80.49 | 27.35 | -9.44 | -11.96 | -26.79 | |||||
EBITDA, 1 Yr. Growth % | 17.39 | 29.53 | -31.36 | -39.98 | 14.02 | |||||
EBITA, 1 Yr. Growth % | 12 | 27.67 | -39.99 | -57.55 | -0.92 | |||||
EBIT, 1 Yr. Growth % | 11.87 | 28.8 | -40.7 | -59.25 | 1.24 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 20.24 | 23.96 | -39.38 | -71.1 | 72.88 | |||||
Net Income, 1 Yr. Growth % | 21.13 | 24.11 | -38.97 | -70.59 | 67.59 | |||||
Normalized Net Income, 1 Yr. Growth % | 10.47 | 33.14 | -39.98 | -60.54 | 0.34 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 20 | 24.07 | -38.81 | -70.73 | 69.44 | |||||
Accounts Receivable, 1 Yr. Growth % | 3.4 | 13.84 | -1.68 | 21.59 | 3.54 | |||||
Inventory, 1 Yr. Growth % | 48.74 | 63.8 | -2.33 | 9.98 | -21.41 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 83.25 | 26.36 | 25.54 | 14.92 | -2.7 | |||||
Total Assets, 1 Yr. Growth % | 31.26 | 15.7 | -2.44 | 2.2 | 0.41 | |||||
Tangible Book Value, 1 Yr. Growth % | 14.3 | 14.46 | 4.81 | -0.81 | 3.99 | |||||
Common Equity, 1 Yr. Growth % | 13.53 | 16.4 | 4.68 | -1.93 | 4.05 | |||||
Cash From Operations, 1 Yr. Growth % | 80.97 | -50.22 | 10.15 | -19.32 | 11.15 | |||||
Capital Expenditures, 1 Yr. Growth % | 2.81 | -11.2 | 47.95 | -29.98 | -54.85 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -207.95 | -124.2 | 158.19 | -54.28 | -176.64 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -208.73 | -123.06 | 165.43 | -54.71 | -179.61 | |||||
Dividend Per Share, 1 Yr. Growth % | 19.51 | 24.49 | -37.7 | -71.05 | 72.73 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 61.99 | 55.42 | 10.82 | -8.1 | -16.87 | |||||
Gross Profit, 2 Yr. CAGR % | 60 | 51.61 | 7.4 | -10.71 | -19.72 | |||||
EBITDA, 2 Yr. CAGR % | 9.15 | 23.16 | -5.66 | -35.65 | -16.73 | |||||
EBITA, 2 Yr. CAGR % | 6.25 | 19.41 | -12.41 | -49.36 | -34.36 | |||||
EBIT, 2 Yr. CAGR % | 5.85 | 19.79 | -12.6 | -50.84 | -35.77 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 15.18 | 22.09 | -13.32 | -58.15 | -29.32 | |||||
Net Income, 2 Yr. CAGR % | 15.58 | 22.61 | -12.97 | -57.63 | -29.79 | |||||
Normalized Net Income, 2 Yr. CAGR % | 6.94 | 21.03 | -10.61 | -51.33 | -37.07 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 9.95 | 22.02 | -12.86 | -57.68 | -29.58 | |||||
Accounts Receivable, 2 Yr. CAGR % | 1.1 | 8.49 | 5.8 | 9.34 | 12.2 | |||||
Inventory, 2 Yr. CAGR % | 50.16 | 56.09 | 26.48 | 3.65 | -7.03 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 87.14 | 52.17 | 25.95 | 20.11 | 5.75 | |||||
Total Assets, 2 Yr. CAGR % | 22.85 | 23.23 | 6.24 | -0.14 | 1.3 | |||||
Tangible Book Value, 2 Yr. CAGR % | 12.34 | 14.38 | 9.53 | 1.96 | 1.56 | |||||
Common Equity, 2 Yr. CAGR % | 11.91 | 14.96 | 10.38 | 1.32 | 1.01 | |||||
Cash From Operations, 2 Yr. CAGR % | 87 | -5.09 | -25.95 | -5.73 | -5.3 | |||||
Capital Expenditures, 2 Yr. CAGR % | 31.98 | -4.45 | 14.62 | 1.78 | -43.78 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 129.91 | -49.38 | -18.75 | 9.02 | -40.52 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 131.4 | -50.4 | -19.49 | 10.02 | -39.65 | |||||
Dividend Per Share, 2 Yr. CAGR % | 15.08 | 21.98 | -11.94 | -57.54 | -29.29 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 57.63 | 49.96 | 32.15 | 2.77 | -12.92 | |||||
Gross Profit, 3 Yr. CAGR % | 56.22 | 48.28 | 27.68 | 0.51 | -16.43 | |||||
EBITDA, 3 Yr. CAGR % | 18 | 15.47 | 1.39 | -18.72 | -21.8 | |||||
EBITA, 3 Yr. CAGR % | 16.34 | 12.86 | -5.02 | -31.05 | -36.15 | |||||
EBIT, 3 Yr. CAGR % | 15.85 | 12.85 | -5.24 | -32.23 | -37.46 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 22.31 | 18.03 | -3.33 | -39.89 | -32.85 | |||||
Net Income, 3 Yr. CAGR % | 22.67 | 18.36 | -2.83 | -39.38 | -33 | |||||
Normalized Net Income, 3 Yr. CAGR % | 15.47 | 14.89 | -4.2 | -31.94 | -38.06 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 18.05 | 14.47 | -3.06 | -39.43 | -32.8 | |||||
Accounts Receivable, 3 Yr. CAGR % | 21.57 | 5.18 | 4.99 | 10.82 | 7.37 | |||||
Inventory, 3 Yr. CAGR % | 58.92 | 54.57 | 33.51 | 20.73 | -5.49 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 67.27 | 64.18 | 42.72 | 22.16 | 11.97 | |||||
Total Assets, 3 Yr. CAGR % | 53.59 | 20.42 | 14 | 4.88 | 0.04 | |||||
Tangible Book Value, 3 Yr. CAGR % | 51.63 | 13.04 | 11.1 | 5.97 | 2.63 | |||||
Common Equity, 3 Yr. CAGR % | 49.16 | 13.39 | 11.42 | 6.12 | 2.22 | |||||
Cash From Operations, 3 Yr. CAGR % | 42.36 | 20.29 | -0.26 | -23.8 | -0.41 | |||||
Capital Expenditures, 3 Yr. CAGR % | 66.98 | 15.65 | 10.54 | -2.74 | -22.38 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 52.1 | 7.85 | -11.25 | -32.77 | -2.75 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 52.45 | 6.6 | -11.57 | -33.39 | -0.9 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | 18.13 | -2.5 | -39.22 | -32.21 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 46.5 | 50.7 | 36.91 | 23.29 | 9.79 | |||||
Gross Profit, 5 Yr. CAGR % | 46.76 | 51.47 | 34.47 | 21.06 | 6.06 | |||||
EBITDA, 5 Yr. CAGR % | 20.79 | 28.45 | 7.84 | -8.59 | -6.19 | |||||
EBITA, 5 Yr. CAGR % | 20.27 | 27.94 | 3.8 | -18.07 | -17.96 | |||||
EBIT, 5 Yr. CAGR % | 19.83 | 28.11 | 3.41 | -19.06 | -18.89 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 23.55 | 34.03 | 6.57 | -22.04 | -14.71 | |||||
Net Income, 5 Yr. CAGR % | 23.76 | 34.3 | 6.93 | -21.53 | -14.68 | |||||
Normalized Net Income, 5 Yr. CAGR % | 19.78 | 31.5 | 4.14 | -18.52 | -19.03 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 17.2 | - | 4.55 | -23.12 | -14.69 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13 | 15.67 | 14.99 | 6.83 | 7.82 | |||||
Inventory, 5 Yr. CAGR % | 36.09 | 52.65 | 45.05 | 31.73 | 15.52 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 42.79 | 50.31 | 49.32 | 44.89 | 26.59 | |||||
Total Assets, 5 Yr. CAGR % | 34.83 | 35.75 | 32.54 | 11.73 | 8.74 | |||||
Tangible Book Value, 5 Yr. CAGR % | 34.09 | 32 | 33.13 | 8.47 | 7.18 | |||||
Common Equity, 5 Yr. CAGR % | 35.22 | 32.28 | 32.24 | 8.4 | 7.14 | |||||
Cash From Operations, 5 Yr. CAGR % | 39.49 | 13.09 | 9.61 | 9.12 | -2.31 | |||||
Capital Expenditures, 5 Yr. CAGR % | 108.48 | 72.2 | 43.65 | 9.89 | -15.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 16.21 | 0.95 | 17.9 | 9.52 | -24.27 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 16.37 | -0.05 | 17.64 | 9.2 | -24 | |||||
Dividend Per Share, 5 Yr. CAGR % | 77.51 | - | - | -21.54 | -14.26 |
Select your edition
All financial news and data tailored to specific country editions
















